30 products | 23 new records + 7 supplemented records

Renal findings at a glance

Start with the action, then check the limitation. Each panel is tied to one identified primary source, not a merged recommendation. Open the full quick answer for tables, exact product scope, units, dates, RX evidence and existing source differences.

No patient dose is calculated. Selected renal passages are not complete monographs or independent clinical approval. No-adjustment guidance does not eliminate monitoring; PK findings do not establish a dialysis regimen.

Current v7.3 updates | Renal measure and dialysis checkpoints | Source-integrity findings

Supplemented existing record

Aztreonam/avibactam - EMBLAVEO

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

This source only - not a merged recommendation

What matters first

Product: Adult IV EMBLAVEO for labeled complicated intra-abdominal infection with concurrent metronidazole; not aztreonam alone.

Renal action / finding: Use the adult loading/maintenance table below, not a component-only dose.
Evidence or dialysis limit: Hemodialysis: administer after the session; no CRRT regimen established here.
Monitoring / application: Reassess changing CrCl; retain metronidazole for cIAI.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Renal measure: Cockcroft-Gault CrCl, mL/min; total combination grams (3:1 aztreonam:avibactam)

Source revision: Revision date not captured in selected review; retrieval date is not revision date.
Selected sections checked: 2026-11-07. Revision and retrieval dates are different.

Full source-specific quick answer All evidence and differences

Supplemented existing record

Desvenlafaxine (Pristiq)

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

This source only - not a merged recommendation

What matters first

Product: Adult PRISTIQ extended-release tablets for major depressive disorder; swallow whole, not divided or crushed.

Renal action / finding: CrCl 30-50: max 50 mg/day; <30: max 25 mg/day or 50 mg every other day.
Evidence or dialysis limit: No supplemental post-dialysis dose.
Monitoring / application: Swallow ER tablets whole; taper rather than abruptly discontinue.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Renal measure: Cockcroft-Gault CrCl, mL/min

Source revision: Revision date not captured in selected review; retrieval date is not revision date.
Selected sections checked: 2026-11-07. Revision and retrieval dates are different.

Full source-specific quick answer All evidence and differences

New exact-product record

Deucravacitinib - SOTYKTU tablets

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

This source only - not a merged recommendation

What matters first

Product: Adult oral SOTYKTU for its labeled indications; renal instruction does not waive other eligibility and safety requirements.

Renal action / finding: No renal adjustment, including ESRD on dialysis.
Evidence or dialysis limit: No CRRT settings or modality-specific schedule supplied in the selected section.
Monitoring / application: Use the explicit renal paragraph; do not use the malformed RX PK range.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Renal measure: Qualitative renal categories, explicitly including ESRD on dialysis

Source revision: Revision date not captured in selected review; retrieval date is not revision date.
Selected sections checked: 2026-11-07. Revision and retrieval dates are different.

Full source-specific quick answer All evidence and differences

New exact-product record

Efgartigimod alfa - VYVGART IV infusion

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

This source only - not a merged recommendation

What matters first

Product: IV VYVGART; not VYVGART HYTRULO; confirm labeled indication and administration presentation.

Renal action / finding: Mild impairment: no adjustment. Moderate/severe: insufficient data.
Evidence or dialysis limit: Moderate eGFR 30-59; severe <30 mL/min/1.73 m2. Dialysis not established.
Monitoring / application: Verify IV versus subcutaneous product and its administration instructions.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Renal measure: Indexed eGFR, mL/min/1.73 m2

Source revision: Revision date not captured in selected review; retrieval date is not revision date.
Selected sections checked: 2026-11-07. Revision and retrieval dates are different.

Full source-specific quick answer All evidence and differences

New exact-product record

Efgartigimod alfa/hyaluronidase - VYVGART HYTRULO subcutaneous

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

This source only - not a merged recommendation

What matters first

Product: Subcutaneous VYVGART HYTRULO; not IV VYVGART; confirm labeled indication and administration presentation.

Renal action / finding: Mild impairment: no adjustment. Moderate/severe: insufficient data.
Evidence or dialysis limit: Moderate eGFR 30-59; severe <30 mL/min/1.73 m2. Dialysis not established.
Monitoring / application: Verify IV versus subcutaneous product and its administration instructions.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Renal measure: Indexed eGFR, mL/min/1.73 m2

Source revision: Revision date not captured in selected review; retrieval date is not revision date.
Selected sections checked: 2026-11-07. Revision and retrieval dates are different.

Full source-specific quick answer All evidence and differences

New exact-product record

Elafibranor - IQIRVO tablets

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

This source only - not a merged recommendation

What matters first

Product: Adult oral IQIRVO for labeled primary biliary cholangitis; baseline renal guidance is distinct from treatment-emergent muscle/kidney toxicity.

Renal action / finding: Mild/moderate/severe impairment: usual dose.
Evidence or dialysis limit: Severe-renal PK study excluded dialysis; no dialysis regimen established.
Monitoring / application: Assess muscle symptoms and myopathy/CPK risk; AKI can accompany rhabdomyolysis.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Renal measure: Renal categories; severe-renal PK study used indexed MDRD eGFR and excluded dialysis

Source revision: Revision date not captured in selected review; retrieval date is not revision date.
Selected sections checked: 2026-11-07. Revision and retrieval dates are different.

Full source-specific quick answer All evidence and differences

New exact-product record

Elranatamab - ELREXFIO subcutaneous injection

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

This source only - not a merged recommendation

What matters first

Product: Adult ELREXFIO subcutaneous therapy for its labeled myeloma setting; not a complete treatment or step-up regimen.

Renal action / finding: Mild/moderate PK finding, not a derived renal dose.
Evidence or dialysis limit: Severe impairment and ESRD effects unknown; no dialysis regimen established.
Monitoring / application: Retain the exact product step-up and safety monitoring requirements.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Renal measure: MDRD eGFR, mL/min as printed

Source revision: Revision date not captured in selected review; retrieval date is not revision date.
Selected sections checked: 2026-11-07. Revision and retrieval dates are different.

Full source-specific quick answer All evidence and differences

New exact-product record

Ensifentrine - OHTUVAYRE inhalation suspension

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

This source only - not a merged recommendation

What matters first

Product: Adult OHTUVAYRE nebulized inhalation suspension for COPD maintenance; not rescue treatment or an injectable product.

Renal action / finding: Mild/moderate: no renal adjustment.
Evidence or dialysis limit: Severe impairment not evaluated; dialysis regimen not established here.
Monitoring / application: Nebulized maintenance therapy, not rescue medication.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Renal measure: Mild/moderate/severe categories; do not turn a supporting PK sample range into a dosing cutoff

Source revision: 10/2026
Selected sections checked: 2026-11-07. Revision and retrieval dates are different.

Full source-specific quick answer All evidence and differences

New exact-product record

Etrasimod - VELSIPITY tablets

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

This source only - not a merged recommendation

What matters first

Product: Adult oral VELSIPITY for labeled ulcerative colitis; renal PK finding only, not a complete prescribing checklist.

Renal action / finding: Severe-renal PK finding; no dose algorithm derived.
Evidence or dialysis limit: Selected passage does not establish dialysis dosing.
Monitoring / application: Apply the full pretreatment and safety checklist, not this PK finding alone.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Renal measure: eGFR <=29 mL/min as printed in selected PK text; indexing not specified there

Source revision: Revision date not captured in selected review; retrieval date is not revision date.
Selected sections checked: 2026-11-07. Revision and retrieval dates are different.

Full source-specific quick answer All evidence and differences

Supplemented existing record

EXBLIFEP - cefepime and enmetazobactam injection

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

This source only - not a merged recommendation

What matters first

Product: Adult IV EXBLIFEP for labeled complicated UTI, including pyelonephritis. Not cefepime alone.

Renal action / finding: Use renal band AND infusion duration in the table.
Evidence or dialysis limit: HD timing is explicit; this is not a CRRT regimen. The source is the 2024 FDA label.
Monitoring / application: Changing renal function: check creatinine/eGFR at least daily.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Renal measure: MDRD eGFR; source table prints mL/min. Indexing is not clarified; do not silently substitute Cockcroft-Gault.

Source revision: 02/2024 FDA approval label; not established as latest label
Selected sections checked: 2026-11-07. Revision and retrieval dates are different.

Full source-specific quick answer All evidence and differences

New exact-product record

Fruquintinib - FRUZAQLA capsules

Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.

This source only - not a merged recommendation

What matters first

Product: Adult oral FRUZAQLA for labeled colorectal cancer; baseline renal PK and treatment-emergent proteinuria are separate decisions.

Renal action / finding: Baseline PK finding is not clearance for on-treatment proteinuria.
Evidence or dialysis limit: No ESRD/dialysis regimen established by the selected PK analysis.
Monitoring / application: Proteinuria >=2 g/24 hours: hold; use quantitative recovery and discontinuation rules below.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Renal measure: Cockcroft-Gault CrCl 15-89 mL/min (PK); proteinuria in g/24 hours (toxicity)

Source revision: Revision date not captured in selected review; retrieval date is not revision date.
Selected sections checked: 2026-11-07. Revision and retrieval dates are different.

Full source-specific quick answer All evidence and differences

Supplemented existing record

Imipenem / cilastatin / relebactam (Recarbrio)

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

This source only - not a merged recommendation

What matters first

Product: Adult IV RECARBRIO renal table only. Pediatric renal categories use a different measure and must be reviewed separately.

Renal action / finding: Adult renal bands below: every 6 hours over 30 minutes.
Evidence or dialysis limit: CrCl <15 without HD: not recommended unless HD starts within 48 hours; PD information inadequate.
Monitoring / application: Do not apply adult CrCl bands to pediatric indexed eGFR.

Selected-section summary, not a complete monograph. Independent clinician review remains pending. Read the exact renal measure, dates and full source below.

Renal measure: Adult Cockcroft-Gault CrCl, mL/min; pediatric >=30 kg uses indexed eGFR, not this adult table

Source revision: Revision date not captured in selected review; retrieval date is not revision date.
Selected sections checked: 2026-11-07. Revision and retrieval dates are different.

Full source-specific quick answer All evidence and differences

What this roundup does not complete

Thirty previously uncovered RX URLs now have selected summaries; five other attempted pages did not yield usable renal text. All 26 A-Z letters still require complete linked-monograph review. The separate historical drug archive was not used.

Counts and remaining-work estimate | v7.2 scope and limitations